{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Geisslinger F"],"funding":["Deutsche Forschungsgemeinschaft"],"pagination":["668"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9343397"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(8)"],"pubmed_abstract":["Despite novel therapy regimens and extensive research, chemoresistance remains a challenge in leukemia treatment. Of note, recent studies revealed lysosomes as regulators of cell death and chemotherapy response, suggesting this organelle is a novel target for chemosensitization. Interestingly, drug-resistant VCR-R CEM acute lymphoblastic leukemia (ALL) cells have an increased expression of the lysosomal cation channel Two-Pore-Channel 2 (TPC2) compared to drug-naïve CCRF-CEM ALL cells. Concurrently, knockout (KO) of TPC2 sensitized drug-resistant VCR-R CEM cells to treatment with cytostatics. The chemosensitizing effect could be confirmed in several cell lines as well as in heterogeneous, patient-derived xenograft ALL cells, using the pharmacological TPC2 inhibitors naringenin and tetrandr"],"journal":["Cell death & disease"],"pubmed_title":["Targeting TPC2 sensitizes acute lymphoblastic leukemia cells to chemotherapeutics by impairing lysosomal function."],"pmcid":["PMC9343397"],"funding_grant_id":["VO 376/19-1","BA 7238/2-1"],"pubmed_authors":["Muller M","Vollmar AM","Geisslinger F","Bartel K","Chao YK","Grimm C"],"additional_accession":[]},"is_claimable":false,"name":"Targeting TPC2 sensitizes acute lymphoblastic leukemia cells to chemotherapeutics by impairing lysosomal function.","description":"Despite novel therapy regimens and extensive research, chemoresistance remains a challenge in leukemia treatment. Of note, recent studies revealed lysosomes as regulators of cell death and chemotherapy response, suggesting this organelle is a novel target for chemosensitization. Interestingly, drug-resistant VCR-R CEM acute lymphoblastic leukemia (ALL) cells have an increased expression of the lysosomal cation channel Two-Pore-Channel 2 (TPC2) compared to drug-naïve CCRF-CEM ALL cells. Concurrently, knockout (KO) of TPC2 sensitized drug-resistant VCR-R CEM cells to treatment with cytostatics. The chemosensitizing effect could be confirmed in several cell lines as well as in heterogeneous, patient-derived xenograft ALL cells, using the pharmacological TPC2 inhibitors naringenin and tetrandr","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-22T05:37:31.462Z","creation":"2025-02-19T00:42:34.354Z"},"accession":"S-EPMC9343397","cross_references":{"pubmed":["35915060"],"doi":["10.1038/s41419-022-05105-z"]}}